ISSN: 2381-8727

Journal international de l'inflammation, du cancer et de la thérapie intégrative

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs


Secondary Lymphedema Prevalence in Head and Neck Cancer Patients

Joey Deng

Context: Since medical procedure, radiation, or potentially chemotherapy disturbs lymphatic designs, harm delicate tissue prompting scar tissue arrangement and fibrosis, and further influence lymphatic capability, patients with head and neck disease might be at high gamble for creating auxiliary lymphedema. However, there are no published statistics on the incidence of secondary lymphedema following treatment for head and neck cancer.

Objective: The point of this study was to analyse pervasiveness of auxiliary lymphedema in patients with head and neck disease.

Methods: The review included 81 patients with head and neck malignant growth who were three months or more post-treatment. The Foldi lymphedema scale was used to stage external lymphedema. A flexible fiber-optic endoscopic or mirror examination revealed internal lymphedema. Internal lymphedema was graded using Patterson's scale.

Results: 75.3% (61 of 81) of the patients had some kind of late-effect lymphedema, according to the findings. Of those, only 9.8% (six out of 61) had an external condition, 39.4% (24 out of 61) only had an internal condition, and 50.8% (31 out of 61) had both types.

Conclusion: Lymphedema is a typical late impact in patients with head and neck malignant growth, and it creates in numerous outer and interior physical areas. During actual assessment and endoscopic techniques, clinicians ought to evaluate patients with head and neck malignant growth for late-impact lymphedema. When lymphedema is observed, it should be considered to be referred for treatment. Lymphedema risk factors and their effects on symptoms, function,and quality of life in patients with head and neck cancer require further investigation.